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Abstract: Prostate cancer (PCa) is one of the preeminent causes of mortality in men worldwide.
Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose and
treat disease, has been shown to be a promising approach for combating PCa. In PCa patients, bone
is one of the most common sites of metastases, and about 90% of patients develop bone metastases.
This review focuses on (i) clinically translated theragnostic radionuclide pairs for the management of
PCa, (ii) radionuclide therapy of bone metastases in PCa, and (iii) a special emphasis on emerging
theragnostic radionuclide pair, Copper-64/Copper-67 (64 Cu/67 Cu) for managing the disease.
Keywords: prostate cancer; theragnostic; theragnostic radionuclide pairs; radionuclide therapy; bone
metastases; 64 Cu/67 Cu
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1. Introduction
Prostate cancer (PCa) is the most commonly diagnosed male malignancy worldwide [1]. Reportedly, PCa is more prevalent in the developed world, where it is a leading
cause of cancer mortality among Swedish men and the second leading cause of cancer
death in the United Kingdom [2]. In the rest of Europe, it is the third most commonly
diagnosed cancer [3]. It is estimated that in 2022, in the United States, newly diagnosed
PCa will account for 14% of all new cancer cases, and the estimated deaths will account for
5.7% of all cancer deaths [4].
A testosterone-reducing drug combined with androgen deprivation therapy is the
first-line therapy for metastatic PCa. Most patients respond to these regimens initially. The
disease, however, advances to metastatic castration-resistant prostate cancer (mCRPC) [5].
At this stage, patient survival may be improved by using theragnostic radionuclide pairs [6].
Theragnostic radionuclide pairs are a combination of diagnostic and therapeutic radionuclides sharing the same target inside the body. They can belong to the same or different
elements and can have similar chemistry and pharmacokinetics. The use of theragnostic radionuclide pairs can be highly beneficial in the management of cancer as well as
other life-threatening diseases. First, a diagnostic radiopharmaceutical is administered
to the patient, and molecular imaging is performed. The findings allow to select a patient who is most likely to benefit from the therapy. Second, the biodistribution of the
diagnostic radiopharmaceutical further helps to determine the possible adverse effects of
therapeutic radiopharmaceutical. Third, the location of the primary lesion and its tumor
volume determined from the pre-therapy scan, the estimated highest whole-body dose, and
critical tissue radiation dose help to calculate a personalized therapeutic dose. Fourth, posttherapy diagnostic radiopharmaceutical help in predicting response to the treatment [7–9]
(Figure 1).
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Amongst the PCa theragnostics, Copper-64 and Copper-67 (64 Cu/67 Cu) is an emerging
theragnostic radionuclide pair. Their nuclear properties are highly suitable for diagnosis
and therapy. The half-life (t 12 ) of 64 Cu is 12.7 h, long enough for uptake and biodistribution
studies of a radiopharmaceutical, including antibodies that may require a longer time for
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localization. Copper-64 is a positron-emitting radionuclide (Eβ + = 0.653 MeV) that permits
positron emission tomography (PET) imaging and has beta emissions (Eβ − max = 0.579 MeV),
which may be useful for theragnostic applications. Copper-67, on the other hand, decays
with beta emissions of (Eβ − max = 0.561 MeV) with t 12 of 2.57 d, long enough to cause tumor
cell killing but short enough not to induce excessive radiation burden to normal tissues.
The coordination chemistry of copper is such that the radionuclides can be linked with
several chelators, peptides, antibodies, and small molecules [17]. Since both belong to the
same element and share similar chemistry, 67 Cu can be used in lieu of 64 Cu for radionuclide
therapy. This paper briefly discusses the production, and clinical applications of 64 Cu/67 Cu
in PCa patients.
Table 1. Half-life and energies of theragnostic duos and therapeutic radionuclides.
Energies in MeV
S.No

Radionuclide

Half-Life

68 Ga

1

177 Lu

Alpha

Beta (Max)

Gamma

Positron

68 min
6.7 d
9.9 d

6

0.496
-

0.208
-

1.92
-

6.0 h
16.9 h

-

2.1

0.140
0.155

-

67 Cu

12.7 h
2.57 d

-

0.579
0.561

0.184

0.653
-

4

223 Ra

11.4 d

6

-

-

-

5

89 Sr

50.5 d

-

1.463

-

-

6

153 Sm

46.3 h

-

0.807

-

-

225 Ac

2
3

99m Tc
188 Re
64 Cu

2. Peptide Receptor Radionuclide Therapy (PRRT)
Increased prostate-specific antigen (PSA) levels are one of the hallmarks of PCa. Expression of prostate-specific membrane antigen (PSMA) is positively linked with PSA levels.
PSMA is a type 2 integral membrane glycoprotein with intracellular, transmembrane, and
extracellular domains. It consists of 750 amino acids and two monomers [18]. PSMA is expressed at low levels in the cytoplasm of normal prostate epithelial cells. In salivary glands,
lacrimal glands, kidneys, and gastrointestinal tract it is overexpressed physiologically [19].
However, in 90–95% of PCa cells, it dwells in the luminal epithelium of prostatic ducts
where it is up to one thousand times more abundant [20]. Moreover, PSMA expression
levels are highest in metastatic and castrate-resistant diseases. This, differential expression
in normal tissues and cancer cells, as well as its ability to be internalized after ligand
binding, make PSMA an appealing target for theragnostics [20,21]. For targeting PCa,
PSMA has been radiolabeled with theragnostic radionuclide pair 68 Ga and 177 Lu. 68 Ga is
a generator-produced positron (1.92 MeV) emitting radionuclide having a t1/2 of 68 min.
Like 68 Ga, 177 Lu is also a trivalent cation with a t1/2 of 6.7 d. Having Eβ − max = 0.496 MeV
for therapy and Eγ = 0.208 MeV (10.4%) for imaging 177 Lu renders itself as an attractive
theragnostic radionuclide [22].
2.1. Gallium-68-Prostate Specific Membrane Antigen-11 (68 Ga-PSMA-11) (Locametz)
68 Ga-PSMA-11

belongs to a class of urea-based, peptidomimetic PSMA inhibitors. It
is indicated for imaging PSMA-positive lesions in men with PCa. Diagnostic imaging is
performed with PET in those patients who have (i) suspected metastases, (ii) are candidates
for definitive therapy, and (iii) with suspected recurrence based on elevated serum PSA
levels [23]. The sensitivity of 68 Ga-PSMA-11 correlates positively with serum PSA levels
and performs relatively well at low PSA levels. A clinical trial in PCa patients reported a
sensitivity of 47% and specificity of 90% [24].
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2.2. Lutetium-177-Prostate Specific Membrane Antigen-617 (177 Lu-PSMA-617) (Pluvicto)
The PSMA-binding therapeutic radioligand 177 Lu-PSMA-617 (177 Lu-vipivotide tetraxetan) is indicated for the treatment of PSMA-positive adult mCRPC patients, who have
previously been treated for androgen receptor pathway inhibition and with taxane-based
chemotherapy (Table 2). A 68 Ga-PSMA-11 pre-therapy scan is performed to determine
PSMA expression in PCa. Those who express PSMA, qualify for 6 cycles of intravenous
administration of 7.4 GBq 177 Lu-PSMA-617 every 6 weeks. The radiopharmaceutical is
distributed in various organs within 2.5 h of injection and 60–70% of which binds to human plasma proteins [9]. 177 Lu-PSMA-617 beta emissions cause DNA damage, resulting
in cytotoxicity in PSMA-expressing and nearby cells [25]. An international, open-label,
phase 3 trial of 177 Lu-PSMA-617 reported imaging-based progression-free survival (PFS)
and overall survival of 8.7 and 15.3 months. Patients reported fatigue, dry mouth, nausea,
anemia, back pain, arthralgia, decreased appetite, constipation, and diarrhea [26]. The
highest mean calculated absorbed dose for lacrimal gland was 92 Gy for the cumulative
administered activity of 44.4 GBq (6 × 7.4 GBq). For salivary gland the dose was 28 Gy, for
the large intestine it was 92 Gy, for kidneys 19 Gy, for urinary bladder 14 Gy and for blood
marrow 1.5 Gy [27]. The primary route of excretion is the kidneys, with a mean terminal
elimination half-life of 41.6 h. Patients with kidney impairment may be more susceptible to
the renal toxicity. A follow-up patient study found a link between cumulative radiation
doses and worsening kidney function after 13 ± 9 months of therapy [28]. However, in
another radioligand therapy study, did not induce deterioration in kidney function as
observed in a subgroup of mCRPC patients having kidney impairment [29].
2.3. Lutetium-177-J591 (177 Lu-J591)
Anti-PSMA monoclonal antibody J591 has been used for targeting mCRPC. A dose of
1665 MBq/m2 given at a 2-week interval showed a median survival of 42.3 months and a
reduction in PSA levels. 79.6% of the patients had positive 68 Ga-PSMA-11 imaging. Patients
with low PSMA expression had poor responses. At high doses, PSA levels decreased with
an increase in overall survival as well as increased toxicity [30]. The authors added that the
cumulative radiation dose was higher when 177 Lu-J591 was administered in fractions.
2.4. Actinium-225-Prostate Specific Membrane Antigen-617 (225 Ac-PSMA-617)
Alpha emitting radionuclides are evaluated for PRRT due to their short penetration
range (50–80 µm) and high linear energy transfer (80–100 keV/µm). The alpha radiations induce double-strand DNA breaks, and DNA cluster breaks causing highly effective
cell killing (Figure 2). 225 Ac is an alpha-emitting radionuclide (6 MeV) with a t1/2 of
9.9 d. A study with 225 Ac-PSMA-617 treatment (100 KBq/kg body weight) showed a
≥90% decline in PSA levels in 82.3% of PCa patients. Furthermore, 88.2% of patients had a
more than 50% decline in lesions avidity, as showed in 68 Ga-PSMA-PET/CT scan (Table 2).
In 64.7% of patients, all the metastatic lesions were completely resolved. There were side
effects in the form of xerostomia, bone marrow toxicity, and renal impairment [31,32].
Table 2. Clinical utility and activity of therapeutic radiopharmaceuticals for prostate cancer and bone
metastases [25,31,33–37].
Radiopharmaceutical

1

Lutetium-177Prostate specific
membrane antigen
(PSMA)-617

Trade Name

Indication

Dose

Outcome

Pluvicto

Treatment of PSMA-positive
adult metastatic Castration
resistant prostate cancer
patients (mCRPC), previously
treated for
androgen receptor pathway
inhibition and with
taxane-based
chemotherapy

6 cycles of
7.4 GBq every
6 weeks

Progression-free
survival—8.7 months,
Overall survival
(OS)—15.3 months

Table 2. Clinical utility and activity of therapeutic radiopharmaceuticals for prostate cancer and
bone metastases [25,31,33–37].
Radiopharmaceutical
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Lutetium-177- Prostate
specific membrane
antigen (PSMA)-617
Radiopharmaceutical

2

2

3

3

4

4
5

5

Actinium-225-

Actinium-225-PSMAPSMA-617
617

Radium-223
chloridechloride
Radium-223
Strontium-89
chloride

Strontium-89 chloride

Trade Name

Indication
Dose
Outcome
5 of 14
Treatment of PSMA-positive adult
metastatic Castration resistant
prostate cancer patients (mCRPC), 6 cycles of 7.4 Progression-free survival—8.7
Table
2. Cont.
Pluvicto
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GBq every 6 months, Overall survival (OS)—
androgen receptor pathway
weeks
15.3 months
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Outcome
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chemotherapy
specific antigen level
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and lesion avidity for
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level
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Gallium-68-PSMA-11
100
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body
weight
positron emission
PSMA expressing mCRPC patients
Gallium-68-PSMA-11
positron
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tomography/computed
emission
tomography/computed
tomography
tomography
cycles, 50
Treatmentof
ofCRPC
CRPC patients
patients and
Treatment
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per kg body
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OS-14.9 months,
Xofigo
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metastases,
per kg
OS-14.9
months,quality
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quality
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of life
weight,
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and nobone
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visceral and kBq
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body 4-week
weight,
of life
metastatic
disease
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every 4-week
Pain relief and improved
Patients with
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Metastron
148 MBq Pain relief and improved quality of
Patients
with
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quality of life
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148 MBq
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life

Samarium-153ethylenediaminetetrame
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37 MBq/kg
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Pain relief

Pain relief
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Figure2.2.Figure
Figureshows
showstumor
tumor
cell
killing
therapeutic
radiopharmaceutical.
particles
Figure
cell
killing
byby
therapeutic
radiopharmaceutical.
BetaBeta
particles
havehave
linear
energy
transfer
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and
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emitting
radionuclides
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andpenetration
penetration
range
few
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cause
or no
efficiency
range
of of
few
micrometers
andand
cause
littlelittle
or no
effect
on
nearby
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cells.
effect on nearby normal cells.

3. Radionuclide Therapy for Bone Metastases
Metastatic PCa cells interact with bone microenvironments and release various growth
factors. These growth factors disturb the tightly regulated intercellular communication
between osteoblasts and osteoclasts and dysregulate their activity. It results in a profusion
of new, disordered bone. In turn, osteoblasts produce growth factors that stimulate the
growth and survival of PCa cells. This bidirectional positive-feedback loop gives rise to
osteoblastic bone metastases, characteristic of PCa, accounting for significant morbidity,
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bone fracture, pain, and even death [36]. Bone-seeking therapeutic radiopharmaceuticals,
having an affinity for hydroxyapatite, have been used for the treatment of bone metastases.
3.1. Radium-223-Chloride (223 RaCl2 ) (Xofigo)
223 RaCl

2 (t1/2 -11.4 d) is an alpha-emitting radiopharmaceutical indicated for treating
CRPC patients with symptomatic bone metastases but no known visceral metastatic disease.
A dose of 50 kBq/kg body weight is administered every 4-week intervals for 6 cycles.
Six injections of 223 RaCl2 per patient have shown overall median survival of 14.9 months,
improved quality of life, favorable safety profiles, and low rates of myelosuppression.
Moreover, the development of skeletal complications was delayed, and the risks of spinal
cord compression were significantly reduced. A 3-year follow-up analysis suggested
long-term safety of 223 RaCl2 as no association was found between 223 RaCl2 treatment and
secondary malignancies [33,38].

3.2. Strontium-89-Chloride (89 SrCl2 ) (Metastron)
Strontium-89 is a beta-emitting radionuclide (Eβ − max = 1.463 MeV) with a t1/2 of
50.5 d. Strontium-89 chloride acts as a calcium analog and is retained in metastatic bone
lesions for much longer period than in normal bone. The recommended dose, which clears
rapidly from the blood, is 148 MBq. Clinical trials have witnessed relief of pain which
usually begins 10–20 d after its administration and lasts up to 6 months, improving the
quality of life [34,39].
3.3. Samarium-153-Ethylenediaminetetramethylenephosphonic Acid
(153 Sm-EDTMP) (Quadramet)
153 Sm has a t

of 46.3 h and emits medium-energy beta-particles and gamma-photons.
A dose of 37 MBq/kg body weight is administered intravenously [35]. 153 Sm-EDTMP is
effective in treating bone metastases due to its fast blood clearance, high bone uptake, and
low nonosseous uptake. Patients often decrease their analgesics. Turner et al. reported
pain alleviation in 65% of patients over 4 to 35 weeks, and in some patients, transitory
myelosuppression and delayed thrombocytopenia were observed. Sartor et al. reported
that repeat dosing in patients (37 MBq/kg body weight) having painful bone metastases
was safe and effective. The treatment is reasonable in patients who still have bone pain
after an initial dose and have adequate hematologic function [40–44].
1/2

3.4. Gallium-68/Lutetium-177 [(bis(Phosphonomethyl)Carbamoyl]
Methyl-7,10-bis(Carboxymethyl)-1,4,7,10 Tetraazacyclododec-1-Yl) Acetic
Acid (68 Ga/177 Lu-BPAMD)
This has been used in PCa patients with widespread and painful skeletal metastases.
A high tumor dose is delivered owing to the long half-life of the 177 Lu (6.7 d), which results
in a considerable decrease in the osteoblastic activity of the bone metastases, as observed in
a subsequent PET/CT using 68 Ga-BPAMD [45,46].
3.5. Technetium-99m Methyl Diphosphonate/Hydroxy Methylene Diphosphonate/Rhenium-188
Hydroxyethylidine Diphosphonate (99m Tc-MDP/HMDP/188 Re-HEDP)
99m Tc

(t1/2 = 6 h, Eγ = 0.140 MeV) and 188 Re (t1/2 = 16.9 h, Eγ = 0.155 MeV (15%),
Eβ max = 2.1 MeV) are transition elements of group VII b of the periodic table and share
similar chemistry. MDP/HMDP and HEDP are molecules with a strong affinity toward
hydroxyapatite present in the actively growing bone. 99m Tc-MDP/HMDP and 188 Re-HEDP
are used for diagnosing bone lesions and their palliative therapy, respectively. It is reported
that multiple injections of 188 Re-HEDP increase the response rate and duration of pain
relief and improve the quality of life with moderate toxic effects [47–49].
−
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4. Copper-64 and Copper-67
Copper is the third most abundant transition trace metal in humans, after iron and
zinc (Zn) [50]. Copper plays a vital role in the metabolic pathways of cells, such as in
neurotransmitter synthesis and pigment formation. Copper is a transition metal with a
mass number 63.55 and an atomic number 29. With electronic configuration [Ar] 3d10 4s1 ,
Copper belongs to group 11 of the periodic table. Copper has multiple oxidation states;
Cu(II) is the most favorable for radiopharmaceutical preparation. Cu(II) is less labile
to ligand exchange because of crystal field stabilizing energy. It can exist in chloride,
nitrate, bromide, etc., forms and is generally stable and soluble in water. Copper has two
naturally occurring and stable isotopes, of which 69.15% is 63 Cu, and 30.85% is 65 Cu. It
has 27 radioactive isotopes and out of these 60 Cu (Eβ + = 2.9 MeV, t1/2 = 23.7 min), 61 Cu
(Eβ + = 1.21 MeV, t1/2 = 3.33 h), 62 Cu (Eβ + = 2.9 MeV, t1/2 = 9.7 min), 64 Cu (Eβ + = 0.653 MeV,
Eβ − max = 0.57 MeV, t1/2 = 12.7 h) and 67 Cu (Eβ − max = 0.561 MeV, t1/2 = 2.57 d) are used
for imaging and radiotherapy [51,52].
4.1. Copper-64
Amongst all the radioactive isotopes of copper, 64 Cu is the most studied owing to its
ideal nuclear properties. Copper-64 decays to Nickel-64 (64 Ni) with Eβ + = 0.653 MeV (17.8%)
and electron capture (43.6%). It also decays to Zinc-64 (64 Zn) with Eβ − max = 0.579 MeV
(38.48%) (Figure 3a). It has a t1/2 of 12.7 h, which is suitable for imaging using small as
well as large molecules such as antibodies and peptides. The relatively short t1/2 of 64 Cu
does not add unnecessary radiation burden to the patient after imaging studies have been
Biomedicines 2022, 10, x FOR PEER REVIEW
8 of 14
performed, and yet, 64 Cu radiopharmaceuticals can be shipped long distances without
excessive radioactivity decay [53].

Figure3.
3. Decay
Decay scheme
scheme of
of (a)
(a) Copper-64
Copper-64(b)
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64 Cu in a reactor, 63 Cu(n,γ)64 Cu or 64 Zn(n,p)64 Cu nuclear
ment
in a cyclotron.
To produce
A suitable
BFC should
have rapid
radiolabeling kinetics, and the radiolabeled complex
63
64 Cu with low specific activity.
reactions
used.
The use
Cu as
the commonly
target, produce
should beare
stable
in vivo
andof
in vitro.
Most
used BFC
for 64Cu are acyclic ligands
64 Zn target requires fast neutron flux and produces 65 Zn (t
d) as an impurity.
1/2 = 245bis(N4-methylthiodiacetyl-bis-N-4-methylthiosemicarbazone
(ATSM), pyruvaldehyde
64 Cu from the reactor. Cyclotron production involves
These
factors
limit
the
availability
of
semicarbazonato (PTSM), polyazamacrocyclic chelators 1,4,8,11-Tetraazacyclotetrade64 Ni(p,n)64 Cu reaction, which is widely used in the US to meet the need for 64 Cu. In this
cane-1,4,8,11-tetraacetic acid (TETA) and 2,2′,2″,2‴-(1,4,7,10-Tetraazacyclododecaneproduction method, enriched nickel (99.6%) is electroplated onto a gold disk or on a copper
1,4,7,10-tetrayl)tetraacetic acid (DOTA), 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic
substrate having a gold layer and bombarded with protons to obtain 64 Cu. It has been
acid (NODAGA), triazacyclononanes 2,2′,2″-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic
reported that bombarding 40 mg Ni with 15.5 MeV protons for 4 h at 60 µA gives 18.5 GBq
acid (NOTA), bicyclic tetraazamacrocycles (cross-bridged analogues of DOTA and
64
Cu. After production, copper is carefully separated from nickel by an ion-exchange
TETA), hexaazamacrocycles (sarcophagines), bispidine and N2S2 type diaminedithiol ligcolumn chromatography [54,55].
ands.
4.3. Copper-64 Radiopharmaceuticals for Imaging Prostate Cancer
4.3.1. Copper-64-Chloride (64CuCl2)
For radiolabeling of biomolecules with 64Cu, a bifunctional chelator (BFC) is needed.
64CuCl2 has also been used to screen patients with PCa. 185–370 MBq 64CuCl2
IonicBFC
A suitable
should have rapid radiolabeling kinetics, and the radiolabeled complex should
administered
good
tumor
to background
It was
shownligands
that the
tracer
be
stable in vivohad
andgiven
in vitro.
Most
commonly
used BFC ratio.
for 64Cu
are acyclic
diacetyldelivered
a
few
nanograms
of
copper
to
cells
and
had
no
known
cytotoxic
effect.
The
rabis-N-4-methylthiosemicarbazone (ATSM), pyruvaldehyde bis(N4-methylthiosemicarbazonato
diotracer
had
a
rapid
blood
clearance.
Dosimetry
studies
in
healthy
volunteers
suggested
(PTSM), polyazamacrocyclic chelators 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid
the liver, intestine, and pancreas as the critical organs [56].

4.3.2. Copper-64-Diacetyl-bis-N-4-Methylthiosemicarbazone (64Cu-ATSM)
In most tumor microenvironments, increased cell proliferation and decreased neoangiogenesis lead to low oxygen levels. In many cases, the hypoxic conditions render tumors
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(TETA) and 2,20 ,200 ,2000 -(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA),
1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), triazacyclononanes 2,20 ,200 (1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid (NOTA), bicyclic tetraazamacrocycles (crossbridged analogues of DOTA and TETA), hexaazamacrocycles (sarcophagines), bispidine and
N2S2 type diaminedithiol ligands.
4.3.1. Copper-64-Chloride (64 CuCl2 )
Ionic 64 CuCl2 has also been used to screen patients with PCa. 185–370 MBq 64 CuCl2
administered had given good tumor to background ratio. It was shown that the tracer
delivered a few nanograms of copper to cells and had no known cytotoxic effect. The
radiotracer had a rapid blood clearance. Dosimetry studies in healthy volunteers suggested
the liver, intestine, and pancreas as the critical organs [56].
4.3.2. Copper-64-Diacetyl-bis-N-4-Methylthiosemicarbazone (64 Cu-ATSM)
In most tumor microenvironments, increased cell proliferation and decreased neoangiogenesis lead to low oxygen levels. In many cases, the hypoxic conditions render tumors
resistant to chemotherapy and radiation therapy. 64 Cu-ATSM has been employed in these
cases as a diagnostic marker for hypoxia imaging to assess the prognosis. In 64 Cu-ATSM,
copper is present in a 64 Cu(II) oxidation state. It is considered that inside the tumor, it gets
reduced to 64 Cu(I), the complex becomes unstable, and 64 Cu is trapped within the tumor.
64 Cu-ATSM has no urinary excretion and can also image PCa [57–60].
4.3.3. Copper-64-Prostate Specific Membrane Antigen-617 (64 Cu-PSMA-617)
Grubmuller et al. examined the diagnostic potential of 64 Cu-PSMA-617 in 29 PCa
patients. The preliminary results demonstrated a high potential of 64 Cu-PSMA-617 for
PET/CT imaging in patients with recurrent disease and in selected patients with locally
advanced disease. The images displayed very high lesion-to-background ratio with excellent resolution of the detected lesions [61]. Using 64 Cu-NODAGA-PSMA another study
examined 23 PCa patients with the recurring disease and a few individuals with advanced
local disease. The lesions detected in the prostate, lymph nodes, and distant metastases
sites were significantly associated with PSA values. 64 Cu-NODAGA-PSMA uptake considerably increased between 30 min and 1–3 h post-injection. The authors concluded that
64 Cu-NODAGA-PSMA PET is stable in vivo and is a promising imaging tool [62].
4.3.4. Copper-64-Sarcophagine-bisPSMA (64 Cu-SAR-bisPSMA)
Clinical trials are ongoing with 64 Cu-SAR-bisPSMA to identify PSMA-expressing
mCRPC. Patient’s recruitment started in 2021 and is currently recruiting [63]. In the phase I
study one administration of 200 MBq 64 Cu-SAR-bisPSMA will be given to the patients for
dosimetric determination, two administrations for dose escalation studies, and three for
cohort expansion study. The purpose of the research is to determine the safety and efficacy
of 67 Cu-SAR-bisPSMA in patients.
4.3.5. Copper-64-TP3805 (64 Cu-TP3805)
Thakur et al. developed and evaluated TP3805, a peptide analog of pituitary adenylate
cyclase-activating peptide (PACAP) having a high affinity for VPAC1 receptors. VPAC1
receptors (a combined for vasoactive intestinal peptide (VIP) and PACAP) are minimally
expressed in normal cells and benign tumors but expressed in high density on many types
of malignant cells. TP3805 was conjugated with N2 S2 (diaminedithiol(N2 S2 -Benzoyl)2 )
chelating agent at the C-terminus and radiolabeled with 64 Cu. A kit was also formulated to
make it convenient for reliable and routine radiolabeling [64].
In a clinical study of 25 PCa patients, PET imaging with 64 Cu-TP3805 identified lesions
in the prostate gland as confirmed by post-surgical histology. Digital autoradiography
(DAR) with 64 Cu-TP3805 identified 98% PCa foci, 100% high-grade intraepithelial neo-
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plasia, and other malignant lesions. For benign lesions, DAR was negative. The study
demonstrated that 64 Cu-TP3805 is highly specific for PCa and merits further investigation [65]. Another study with 64 Cu-TP3805 in urothelial bladder cancer patients (n = 19)
clearly visualized the lesions due to negligible urinary excretion [66]. 64 Cu-TP3805 can
also identify other malignant lesions and bone metastases. In a clinical study of 19 breast
cancer patients [67], positron emission mammography uptake value/background value
ratios of the 15 min, post-injection images did not alter significantly for up to 5 h of imaging
indicating high in vivo stability of 64 Cu-TP3805.
Hence, it was proposed that 67 Cu-TP3805, with excellent theragnostic qualities
(Tables 3 and 4), can be used for PRRT in PCa patients. A few advantages of 67 Cu-TP3805
over existing PRRT 177 Lu-PSMA-617 are:
requires a pre-therapy scan with 68 Ga-PSMA-11. On the other hand,
VPAC receptors are expressed in all PCa patients, eliminating the need for a patient
qualifying pre-therapy scan.
(ii) 177 Lu-PSMA-617 therapy may requires amino acid and botulinum toxin pretreatment.
However, 67 Cu-TP3805 has no uptake in salivary glands. Hence, can treat patients
without undergoing multiple pretreatment procedures.
(iii) 67 Cu-TP3805 has no urinary excretion and can treat bladder cancer, primary PCa their
metastatic lesions as well as involved lymph nodes.
(iv) Cancer stem cells express VPAC receptors [68,69] and can be targeted with 67 CuTP3805, perhaps preventing recurrence of the disease.
(i)

177 Lu-PSMA-617

Table 3. Comparison of characteristics of radionuclide 67 Cu and 177 Lu.

Half-life (d)
Beta tissue range (mm)

67 Cu

177 Lu

2.6

6.7

0.6

0.6

−

Eβ max —0.561
Eγ —0.184

Energies (MeV)

−

Eβ max —0.496
Eγ —0.208

Hospitalization required

No

No

Production method

Accelerator

Reactor

Table 4. Comparing theragnostic characteristics of 67 Cu-TP3805 with 177 Lu-PSMA.
Characteristics

177 Lu-PSMA

67 Cu-TP3805

Advantages of 67 Cu-TP3805

Tissue range (mm)

0.6

0.6

•

Same as 177 Lu

Receptor expression on
prostate cancer (PCa)

80–85%

100%

•
•

No patient screening procedure required
100% of the PCa patients can be treated

Tissue distribution
Salivary glands

Yes

No

•
•

No xerostomia
No botulinum toxin pretreatment required

Renal

Yes
(cortex and medulla)

Cortex only

•
•

No renal damage
No amino acid treatment required

Bladder

Yes

No

•

Primary PCa lesion can be diagnosed and treated

Metastatic lesions

Yes

Yes

•

All distant metastatic lesions can be treated

Cancer stem cells

No

Yes [69,70]

•
•

Cancer stem cells can be targeted
Minimize recurrence
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4.4. Production of Copper-67
Copper-67 decays to 67 Zn with Eβ − max = 0.561 MeV, Eγ = 0.184 MeV (48.7%) and
a t1/2 of 2.57 d (Figure 3b) [17]. Although 67 Cu can be produced from the reactor, the
low yield and expensive target material (67 Zn) limit the availability of reactor-produced
67 Cu. In a cyclotron, 67 Cu can be produced using Zn, Ni, Cu, and Ga as target material
(Table 5). The main route of production using Zn as the target material is a 68 Zn(p,2p)67 Cu
reaction with proton-beam energy 38–50 MeV. Enriched 68 Zn targets not only enhance 67 Cu
yield but also reduce co-production of other Cu-radionuclides. At the proton beams of
up to 30 MeV, the 70 Zn(p,α)67 Cu reaction is feasible without the co-production of 64 Cu.
The reaction requires enriched 70 Zn (95.47%), which is expensive and makes recovery and
re-use of the irradiated target material a vital task. Using deuteron beams of 7–25 MeV
70 Zn(d,x)67 Cu reaction seems promising also [70]. Alpha beams are used to irradiate nickel
in a 64 Ni(α,p)67 Cu reaction, but the reaction has a low yield. Production of 67 Cu using
65 Cu(α,2p)67 Cu reaction yields 67 Cu with a very low specific activity. Production of 67 Cu
from Ga using 71 Ga(p,x)67 Cu nuclear reaction requires 20–40 MeV proton beam energy
and 24 h irradiation time. The disadvantages of the reaction are low yield and high 64 Cu
contamination. Furthermore, the low melting point of gallium makes target preparation
difficult for nuclear bombardment [71–77].
Table 5. Nuclear reactions for Copper-67 production and yields [70].
67 Cu

(MBq/µA)

Nuclear Reaction

Energy Range
(MeV)

End of Bombardment

After 72 h Cooling Time

68 Zn(p,2p)67 Cu

50–38

166

74

70 Zn(p,α)67 Cu

24–8

113

50.6

70 Zn(d,x)67 Cu

25–7

123

54.9

64 Ni(α,p)67 Cu

33–9

18.9

8.4

71 Ga(p,x)67 Cu

40–20

12.5

5.6

Note: Data given in the table for the nuclear reactions are reported with enriched target and 24 h irradiation time.

Photonuclear production using 68 Zn(γ,p)67 Cu reaction is another method for 67 Cu production. It is reported that bombarding 55.5 g enriched 68 Zn with 40 MeV bremsstrahlung
photons in electron linear accelerator for 53.5 h gives 62.9 GBq activity and >1850 Bq/mg
67 Cu at the end of bombardment (EOB) without detecting 64 Cu as a contaminant. The
enriched target material is mandatory to avoid the co-production of zinc and copper
radionuclides as impurities [78].
4.5. Copper-67 Radiopharmaceutical for Prostate Cancer Therapy
Copper-67-Sarcophagine-bis-Prostate Specific Membrane Antigen (67 Cu-SAR-bisPSMA)
Clinical trials are being conducted to investigate the safety and efficacy of 67 Cu-SARbisPSMA in PSMA-expressing mCRPC patients [63]. Patients will receive two doses at the
recommended dose level determined by dose escalation during the cohort expansion phase.
5. Conclusions
PCa theragnostics involve various radiopharmaceuticals that target both primary
lesions as well as bone metastases. FDA approved, 177 Lu-PSMA-617 increases OS and
imaging-based PFS in PCa patients. In mCRPC patients, targeted alpha therapy (TAT)
with 225 Ac-PSMA-617 causes relatively low toxicity; hence, it is an effective and safe
treatment option. However, clinical trials are required to compare the therapeutic effects
and survival benefits with existing clinical treatments. TAT of bone metastases in PCa with
223 RaCl remains an important component of the treatment paradigm as it has proven
2
survival benefits. Tumor-specific TAT seems promising due to its high therapeutic efficiency,
minimal damage to normal tissue, and ability to target small volume disease. 89 SrCl2 and
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153 Sm-EDTMP

enable pain relief and improve the quality of life of PCa patients having
bone metastases.
64 Cu and 67 Cu are chemically identical radionuclides. Both have similar in vivo behavior which facilitates the use of the former as a predictor of the biodistribution and toxicity of
the latter. Moreover, a 64 Cu pre-therapy dosimetry scan helps calculate a personalized 67 Cu
patient therapy dose. 67 Cu-bisPSMA and 67 Cu-TP3805 are emerging radiopharmaceuticals
for PCa theragnostics. The efficient and optimized production methods yielding large
amounts of 64 Cu and 67 Cu with high specific activity can enhance routine availability and
enable its more widespread use.
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